肝细胞移植治疗肝病的研究进展  

Research Progress in Hepatocyte Transplantation for Liver Disease Treatment

作　　者：曾颖星 郑永霞[1] 徐艳雯 晏牧熙 沈斌 ZENG Yingxing;ZHENG Yongxia;XU Yanwen;YAN Muxi;SHEN Bin(Medical College,Jiaxing University,Jiaxing 314001,China)

机构地区：[1]嘉兴学院医学院,浙江嘉兴314001

出　　处：《医学综述》2018年第7期1344-1348,共5页Medical Recapitulate

基　　金：浙江省大学生科技创新活动计划(2017R417012)

摘　　要：肝病的发病率和病死率均很高。目前,肝移植仍是终末期肝衰竭的唯一有效的治疗方法,但供体器官的可用性非常有限。经过数十年的发展,肝细胞治疗技术有了长足的进步,特别是肝细胞移植用来治疗肝为基础的代谢紊乱,急性或慢性肝功能衰竭等疾病。与原位肝移植相比,肝细胞移植具有供体细胞来源充足、创伤小、成本低、操作简单等优势,使其在治疗终末期肝病和代谢性肝病中发挥重要作用。然而,肝细胞移植仍然存在供体细胞活力低,数量少,移植后容易发生免疫排斥以及增殖不足等缺点,制约着肝细胞移植的发展。The incidence and mortality of liver disease are very high.So far,liver transplantation remains the only effective treatment for end-stage liver failure but is limited by the availability of donor organs.After decades of development,cell therapy in people has taken the form of hepatocyte transplantation for metabolic disorders with a hepatic basis,and for acute or chronic liver failure.Compared to orthotopic liver transplantation,hepatocyte transplantation is featured with the advantages of sufficient resource,small trauma,easy to operate and affordable,so it plays an important role in the treatment of end-stage liver disease and metabolic liver disease.However,hepatocyte transplantation still has some disadvantages,such as low activity,small number of donor cells,easy rejection and lack of proliferation after transplantation,restricting the development of hepatocyte transplantation.

关 键 词：细胞治疗 干细胞 肝脏再生 代谢性肝病 肝硬化 

分 类 号：R319[医药卫生—基础医学]